GRACE :: Radiation Oncology

Search cancerGRACE.org

Treatment for “solitary” brain metastases: What is best?

Share
download as a pdf file Download PDF of this page

A great challenge posed to many lung cancer patients is spread of lung cancer to the brain. Indeed this is a scary event, for which no one can be adequately prepared. Fortunately however, many treatment options do exist which can effectively control brain metastases in many cases. In general, surgery and radiation are the key tools to address cancer when it has spread to the brain. Chemotherapy and other systemic therapies typically do not penetrate the brain region very well, and hence are not particularly active against brain metastases.

For solitary brain metastasis, surgery is often employed upfront for both diagnosis and therapy. The term solitary (as opposed to “single”) is often used to connote the presence of no additional cancer metastases elsewhere in the body. In the case of a solitary brain metastasis, there is sometimes doubt as to whether a brain lesion is in fact a metastasis. In this case, surgical biopsy or resection of the suspect lesion can confidently rule out other possibilities such as infection or a primary brain tumor. Surgery also can decompress swelling and help reduce any associated symptoms that a lesion may be causing. Of course, surgery also can carry risks, though in most cases the neurosurgeon can accurately assess risks prior to surgery based on the location of the lesion within the brain. Neurosurgeons also have a wide variety of techniques available to them in order to be sure that the surgical procedure is not causing injury. Often part of the surgery may be done while the patient is awake – achieving the ultimate careful assessment of neurological function during surgery.

Following surgery for a solitary brain metastasis, the greatest area at risk for metastatic progression in the brain is the very site from which the initially detected metastasis was surgically resected. This area is at very high risk – there is approximately a 70-80% risk of metastatic progression at this initial site following surgery alone. Elsewhere in the brain following surgery for a solitary brain metastasis, the risk of detecting additional metastases over the next year is approximately 50% – still a very high-risk, but not quite as high as the site of the initial metastatic lesion. In order to address the risks of cancer relapse at the initial site of disease or elsewhere in the brain, we consider whole brain radiotherapy, and often as an alternative to whole brain radiotherapy, stereotactic radiosurgery to the surgical resection cavity alone. Surgery followed by whole brain irradiation is a more traditional approach. As well, surgery + whole brain irradiation (in comparison to surgery alone) has been shown to be superior at preventing neurologic death, though not overall survival in a randomized trial. Whereas, surgery followed by stereotactic radiosurgery to the resection cavity (without whole brain irradiation) is an evolving paradigm, without the support of a randomized trial, though with good reported outcomes in non-randomized studies.

The pivotal question is: for which patients with a solitary brain metastasis, is surgery followed by radiosurgery to the resection cavity enough, obviating the need for immediate whole brain radiotherapy? This is a question which many patients face, and one for which there is no standard answer. It really depends on many factors surrounding the patient, his or her disease, goals, and greatest concerns. In general, surgery followed by stereotactic radiosurgery to the surgical resection cavity is safe and effective, addressing the brain area at the highest risk of recurrence and diminishing that risk significantly. Stereotactic radiosurgery “boost” to the resection cavity does not carry the side effect profile of whole brain irradiation, though does not decrease the risk of developing other areas of metastasis within the brain. While whole brain irradiation addresses both the initial site of resected metastasis as well as the rest of the brain, there is potential for greater side effects, though sometimes the true risks associated with whole brain radiation are exaggerated.

If whole brain irradiation is deferred in favor of stereotactic radiosurgery, close followup is very important – repeat brain MRIs on a regular interval are necessary. That being said, close followup is important even if whole brain irradiation is performed as well. Though the risk of other brain metastases drops with whole brain irradiation down from 50%, it does not drop to zero. Even after whole brain irradiation, there is a risk of 10-30% of developing additional brain metastases.

What about radiation therapy alone for a solitary brain metastasis? It has been shown that surgery + whole brain irradiation is better than whole brain irradiation alone – in fact, a study comparing these two treatments showed that surgery preceding whole brain irradiation led to significantly improved overall survival (Patchell et al., New England Journal of Medicine, 1990). However, for some patients that are not good candidates for surgery or surgery is not considered to be of benefit, stereotactic radiosurgery may offer excellent local control of a solitary lesion, by itself or in combination with whole brain irradiation. As well, in some situations, simple whole brain radiation, all by itself, may be the best therapy. Again, the best path of treatment is very specific to a patient’s individual circumstances. There are a multitude of options.


4 Responses to Treatment for “solitary” brain metastases: What is best?

  • ts says:

    Thank you Dr. Loiselle.
    The difference between a solitary brain met and a single brain met is an eye opener. It stands to reason that brain surgery doesn’t make much sense for a patient with clear metastatic lung cancer, but I hadn’t thought of it that way.
    I assume for a single brain met, some form of stereotactic radiosurgery with of without WBR is the standard of care? (I’m sure there are lots of posts on this, but am feeling a little lazy this afternoon.)

  • Dr Loiselle says:

    Hi TS –

    I would say that for a solitary lesion and all else favorable, that surgery followed by some form of radiation is standard of care. I think that either whole brain or more focused radiation are both commonly practiced, and both are reasonable.

  • FaithAndHope79 says:

    Dr. Loiselle, I have a question not related to this subject. When I started Tarceva more than four years age, a family friend whose relative had lung cancer and was on Tarceva told me and my husband that Tarceva could prevent cancer from traveling to the brain. And I have noticed the same “statement” a quite few times on inspire.com. I believed it in the beginning and felt quite lucky, but now I am not sure. Could doctors give us some comments on that?

    Thank you,
    Jing

  • Dr West
    Dr West says:

    The answer is that this isn’t correct. In fact, many of us who treat a large number of patients with lung cancer who are treated with Tarceva for a long time, particularly those with an EGFR mutation, seem to relapse in the brain, with brain mets or with meningeal carcinomatosis, a little more commonly. However, I don’t think that the data support that central nervous system relapses are more common in patients on EGFR inhibitors for a long time, but I definitely know of no evidence that they prevent people from ever having brain relapses.

    I think the misinformation comes from the fact that EGFR TKIs like Tarceva and Iressa can definitely lead to responses in the brain among people who have brain metastases. And there is a little bit of data that a different, pulsed dosing schedule of Tarceva may be somewhat effective as a treatment for meningeal carcinomatosis, which otherwise is extremely limited in terms of treatment alternatives.

    -Dr. West

Leave a Reply

Ask Us, Q&A
Radiation Oncology Expert Content

Archives

Share
download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
download as a pdf file Download PDF of this page

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

Share
download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share
download as a pdf file Download PDF of this page

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243